INAUGURAL ARTICLE by a Recently Elected Academy Member:From the Cover: Neutralization of terminal differentiation in gliomagenesis

An immature state of cellular differentiation—characterized by stem cell–like tendencies and impaired differentiation—is a hallmark of cancer. Using glioblastoma multiforme (GBM) as a model system, we sought to determine whether molecular determinants that drive cells toward terminal differentiation are also genetically targeted in carcinogenesis and whether neutralizing such genes also plays an active role to reinforce the impaired differentiation state and promote malignancy. To that end, we screened 71 genes with known roles in promoting nervous system development that also sustain copy number loss in GBM through antineoplastic assay and identified A2BP1 (ataxin 2 binding protein 1, Rbfox1), an RNA-binding and splicing regulator that is deleted in 10% of GBM cases. Integrated in silico analysis of GBM profiles to elucidate the A2BP1 pathway and its role in glioma identified myelin transcription factor 1-like (Myt1L) as a direct transcriptional regulator of A2BP1. Reintroduction of A2BP1 or Myt1L in GBM cell lines and glioma stem cells profoundly inhibited tumorigenesis in multiple assays, and conversely, shRNA-mediated knockdown of A2BP1 or Myt1L in premalignant neural stem cells compromised neuronal lineage differentiation and promoted orthotopic tumor formation. On the mechanistic level, with the top-represented downstream target TPM1 as an illustrative example, we demonstrated that, among its multiple functions, A2BP1 serves to regulate TPM1’s alternative splicing to promote cytoskeletal organization and terminal differentiation and suppress malignancy. Thus, in addition to the activation of self-renewal pathways, the neutralization of genetic programs that drive cells toward terminal differentiation may also promote immature and highly plastic developmental states that contribute to the aggressive malignant properties of GBM.

[1]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[2]  A. Sloan,et al.  Angiogenesis , Metastasis , and the Cellular Microenvironment Cadherin-11 , a Marker of the Mesenchymal Phenotype , Regulates Glioblastoma Cell Migration and Survival In Vivo , 2012 .

[3]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[4]  E. Jonasch,et al.  Ras- and Raf-induced Down-modulation of Non-muscle Tropomyosin Are MEK-independent* , 1998, The Journal of Biological Chemistry.

[5]  R. Braverman,et al.  Suppression of Neoplastic Transformation and Regulation of Cytoskeleton by Tropomyosins , 1998, Somatic cell and molecular genetics.

[6]  J. Rich,et al.  Cancer stem cells in brain tumor biology. , 2008, Cold Spring Harbor symposia on quantitative biology.

[7]  Thomas Vierbuchen,et al.  Direct conversion of fibroblasts to functional neurons by defined factors , 2010, Nature.

[8]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[9]  S. Lipton,et al.  Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. , 2011, Cell stem cell.

[10]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[11]  Ulrich Pfisterer,et al.  Direct conversion of human fibroblasts to dopaminergic neurons , 2011, Proceedings of the National Academy of Sciences.

[12]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[13]  S. Sugano,et al.  A vertebrate RNA‐binding protein Fox‐1 regulates tissue‐specific splicing via the pentanucleotide GCAUG , 2003, The EMBO journal.

[14]  M. Nicholas,et al.  Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. , 2011, Seminars in oncology.

[15]  R. Fuldner,et al.  Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[17]  Thomas Vierbuchen,et al.  Induction of human neuronal cells by defined transcription factors , 2011, Nature.

[18]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[19]  L. Chin,et al.  Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer , 2012, Cell.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[22]  Neelroop Parikshak,et al.  RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. , 2012, Human molecular genetics.

[23]  N. Harindranath,et al.  Suppression of src-induced transformed phenotype by expression of tropomyosin-1 , 1999, Oncogene.

[24]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.

[26]  K. Hess,et al.  Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme , 2006, Journal of Neuro-Oncology.

[27]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[28]  Richard Beyer,et al.  TWIST1 promotes invasion through mesenchymal change in human glioblastoma , 2010, Molecular Cancer.

[29]  K. Kaibuchi,et al.  Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway , 2001, Oncogene.

[30]  Jordan M. Komisarow,et al.  RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts , 2006, Nature Protocols.

[31]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[32]  P. Loehrer Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .

[33]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[34]  D. Helfman,et al.  Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[36]  K. Nabeshima,et al.  Expression of c‐Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study , 1997, Histopathology.

[37]  D. Black,et al.  An inducible change in Fox-1/A2BP1 splicing modulates the alternative splicing of downstream neuronal target exons. , 2009, Genes & development.

[38]  Andrei V Bakin,et al.  Ras alters epithelial-mesenchymal transition in response to TGF-β by reducing actin fibers and cell-matrix adhesion , 2009, Cell cycle.

[39]  K. Hess,et al.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[40]  Yonghong Xiao,et al.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. , 2010, Cancer cell.

[41]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[42]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Li Li,et al.  MicroRNA-mediated conversion of human fibroblasts to neurons , 2011, Nature.

[44]  S. Sakiyama,et al.  Suppression of synthesis of tropomyosin isoform 2 in metastatic v-Ha-ras-transformed NIH3T3 cells. , 1988, Biochemical and biophysical research communications.

[45]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[46]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[47]  D. Helfman,et al.  Tropomyosin as a regulator of cancer cell transformation. , 2008, Advances in experimental medicine and biology.

[48]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[49]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[50]  Istvan Mody,et al.  The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain , 2011, Nature Genetics.

[51]  Peter Stoilov,et al.  Homologues of the Caenorhabditis elegans Fox-1 Protein Are Neuronal Splicing Regulators in Mammals , 2005, Molecular and Cellular Biology.